Drug Trial Radar · NCT05590585
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Jan 11, 2023
Primary completion
Nov 14, 2024
Study completion Nov 14, 2024
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Oct 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in your blood at different times * How much the study drug improves quality of life and mental health
Conditions
- Moderate-to-Severe Atopic Dermatitis
- Atopic Eczema
Interventions
dupilumabDrug
Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
Topical emollient (moisturizer)Other
Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)Time frame: Week 24
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Total Skin & Beauty Dermatology Center
Birmingham, Alabama
The University Of Alabama At Birmingham
Birmingham, Alabama
C2 Research Center, LLC
Montgomery, Alabama
Center for Dermatology Clinical Research, inc.
Fremont, California
UCSD/ Rady Children's Hospital
San Diego, California
UCSF
San Francisco, California
SF Research Institute
San Francisco, California
University of Miami Miller School of Medicine
Miami, Florida
Skin and Cancer Associates, LLP
Miami, Florida
Century Research LLC
Miami, Florida
Advanced Medical Research PC
Atlanta, Georgia
Atlanta Biomedical Clinical Research LLC
Atlanta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Callender Dermatology and Cosmetic Center
Glenn Dale, Maryland
Dermatology and Skin Cancer Specialists, LLC dba US Dermatology Partners
Rockville, Maryland
Wayne State University Physician Group Dermatology
Dearborn, Michigan
Revival Research Institute , LLC
Troy, Michigan
Washington University School of Medicine
St Louis, Missouri
Rao Dermatology
Atlantic Highlands, New Jersey
SUNY Downstate Medical Center
Brooklyn, New York
NYC Health + Hospital , Elmhurst Hospital Center
Elmhurst, New York
Markowitz Medical
New York, New York
Philip Fried, MD PLLC
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
Oregon Health & Science University
Portland, Oregon
National Allergy and Asthma Research, LLC.
North Charleston, South Carolina
Center for Clinical Studies, LTD.LLP
Houston, Texas
Heights Dermatology & Aesthetic Center - Heights Location
Houston, Texas
RFSA Dermatology
San Antonio, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.